Top

Journal of Neurology

Published in:

23-08-2023 | Paraneoplastic Cerebellar Degeneration | Short Commentary

A retrospective study of autoimmune cerebellar ataxia over a 20-year period in a single institution

Authors: Akihiko Kudo, Hiroaki Yaguchi, Keiko Tanaka, Akio Kimura, Ichiro Yabe

Published in: Journal of Neurology | Issue 1/2024

Abstract

Background

It is important to differentiate autoimmune cerebellar ataxia (ACA) from neurodegenerative CA, but this is sometimes difficult. We performed a retrospective study in a single institution in Japan over a 20-year period to reveal the clinical features of ACA.

Methods

Patients with CA as the primary neurological symptom were enrolled from those admitted to the Department of Neurology, Hokkaido University Hospital between April 2002 and March 2022. ACA was diagnosed retrospectively according to the following criteria: (1) CA being the predominant symptom; (2) identification of cancer within 2 years of onset; (3) improvement in cerebellar symptoms following immunotherapy; and (4) ruling out alternative causes of CA. Patients fulfilling criteria (1), (2), and (4) were classified as paraneoplastic cerebellar degeneration (PCD), while those fulfilling (1), (3), and (4) were classified as non-PCD and enrolled as patients with ACA. Neurodegenerative diseases, e.g., multiple system atrophy (MSA), were confirmed retrospectively based on generally used diagnostic criteria and enrolled. Furthermore, the ACA diagnostic criteria proposed by Dalmau and Graus were applied retrospectively to the ACA patients to examine the validity of the diagnoses.

Results

Among the 243 patients with CA, 13 were enrolled as ACA; five were PCD and eight were non-PCD. Eight of these cases met the proposed diagnostic criteria by Dalmau and Graus. MSA was the most prevalent disease among CA patients, with 93 cases. The incidence of cerebellar atrophy was significantly lower in ACA (3/13) than in MSA (92/92). Cerebrospinal fluid (CSF) pleocytosis was significantly more frequent in ACA than in MSA (4/13 vs. 2/55, respectively). However, there was no significant difference in the presence of oligoclonal bands, increased protein in CSF, and laterality differences in ataxia.

Conclusion

ACA was present in ~ 5% of Japanese CA patients. The absence of cerebellar atrophy, despite the presence of CA, strongly supports ACA over MSA. While CSF pleocytosis was observed more often in ACA, the positivity rate was only ~ 30%. Since ACA is treatable, further studies are needed to identify additional clinical features and accurate diagnostic biomarkers.

Dalmau J, Graus F (2022) Autoimmune encephalitis and related disorders of the nervous system. Cambridge University Press, CambridgeCrossRef

Flanagan EP et al (2022) Autoimmune encephalitis misdiagnosis in adults. JAMA Neurol 80:30–39CrossRefPubMedCentral

Graus F et al (2021) Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 8(4):e1014CrossRefPubMedPubMedCentral

Muniz-Castrillo S et al (2022) Novelties in autoimmune and paraneoplastic cerebellar ataxias: twenty years of progresses. Cerebellum 21:573CrossRefPubMed

Spatola M et al (2020) Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis. Neurology 95(22):e3012–e3025CrossRefPubMedPubMedCentral

Dougherty K, Covarrubias M (2006) A dipeptidyl aminopeptidase-like protein remodels gating charge dynamics in Kv4.2 channels. J Gen Physiol 128(6):745–753CrossRefPubMedPubMedCentral

Bürk K et al (2010) Antineuronal antibodies in sporadic late-onset cerebellar ataxia. J Neurol 257(1):59–62CrossRefPubMed

Becker EB et al (2012) Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry 83(4):437–440CrossRefPubMed

Honnorat J et al (2001) Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol 58(2):225–230CrossRefPubMed

10.

Jarius S et al (2010) A new Purkinje cell antibody (anti-Ca) associated with subacute cerebellar ataxia: immunological characterization. J Neuroinflamm 7:21CrossRef

11.

Hadjivassiliou M et al (2020) Diagnostic criteria for primary autoimmune cerebellar ataxia-guidelines from an international task force on immune-mediated cerebellar ataxias. Cerebellum 19(4):605–610CrossRefPubMedPubMedCentral

12.

Landa J et al (2021) Encephalitis with autoantibodies against the glutamate kainate receptors GluK2. Ann Neurol 90(1):101–117CrossRefPubMed

13.

Abe M et al (2023) Sez6l2 autoimmunity in a large cohort study. J Neurol Neurosurg Psychiatry 94:667–668CrossRefPubMed

14.

Landa J et al (2021) Seizure-related 6 homolog like 2 autoimmunity. Neurol Neuroimmunol Neuroinflamm 8(1):e916CrossRefPubMed

15.

Wenning GK et al (2022) The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov Disord 37(6):1131–1148CrossRefPubMedPubMedCentral

16.

Sasaki H et al (2000) Prevalence of triplet repeat expansion in ataxia patients from Hokkaido, the northernmost island of Japan. J Neurol Sci 175(1):45–51CrossRefPubMed

17.

Tsuji S et al (2008) Sporadic ataxias in Japan—a population-based epidemiological study. Cerebellum 7(2):189–197CrossRefPubMed

18.

Yoshida K et al (2018) Idiopathic cerebellar ataxia (IDCA): diagnostic criteria and clinical analyses of 63 Japanese patients. J Neurol Sci 384:30–35CrossRefPubMed

19.

Gilman S et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(9):670–676CrossRefPubMedPubMedCentral

20.

Nakamura M et al (2010) MERRF/MELAS overlap syndrome: a double pathogenic mutation in mitochondrial tRNA genes. J Med Genet 47(10):659–664CrossRefPubMed

21.

Höglinger GU et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32(6):853–864CrossRefPubMedPubMedCentral

22.

Koga S et al (2016) Cerebellar ataxia in progressive supranuclear palsy: an autopsy study of PSP-C. Mov Disord 31(5):653–662CrossRefPubMedPubMedCentral

23.

Shimohata T et al (2015) Clinicopathological features and diagnostic criteria for progressive supranuclear palsy with predominant cerebellar ataxi. Mov Disord 30(Supple1):847

24.

Schmitz-Hubsch T et al (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66(11):1717–1720CrossRefPubMed

25.

Yaguchi H et al (2014) Identification of anti-Sez6l2 antibody in a patient with cerebellar ataxia and retinopathy. J Neurol 261(1):224–226CrossRefPubMed

26.

Hadjivassiliou M et al (2017) Causes of progressive cerebellar ataxia: prospective evaluation of 1500 patients. J Neurol Neurosurg Psychiatry 88(4):301–309CrossRefPubMed

27.

Nanri K et al (2014) Gluten ataxia in Japan. Cerebellum 13(5):623–627CrossRefPubMed

28.

Liu M et al (2023) Autoimmune cerebellar ataxia: etiology and clinical characteristics of a case series from China. Cerebellum 22(3):379–385CrossRefPubMed

29.

Mitoma H et al (2016) Consensus paper: neuroimmune mechanisms of cerebellar ataxias. Cerebellum 15(2):213–232CrossRefPubMed

30.

Damato V et al (2022) Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the scale for the assessment and rating of ataxia. Eur J Neurol 29(2):564–572CrossRefPubMed

31.

Hill EJ, Jankovic J (2021) Antiglutamic acid decarboxylase 65 antibody-associated hemiataxia. Neurol Clin Pract 11(4):e564–e566CrossRefPubMedPubMedCentral

32.

Gaig C et al (2021) Frequency and characterization of movement disorders in anti-IgLON5 disease. Neurology 97(14):e1367–e1381CrossRefPubMedPubMedCentral

33.

Nakamura M et al (2008) Transient subacute cerebellar ataxia in a patient with Lambert–Eaton myasthenic syndrome after intracranial aneurysm surgery. Clin Neurol Neurosurg 110(5):480–483CrossRefPubMed

34.

Yaguchi H et al (2018) Anti-Sez6l2 antibody detected in a patient with immune-mediated cerebellar ataxia inhibits complex formation of GluR1 and Sez6l2. J Neurol 265(4):962–965CrossRefPubMed

35.

Honnorat J et al (2009) Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 80(4):412–416CrossRefPubMed

36.

Graus F et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15(4):391–404CrossRefPubMedPubMedCentral

Title: A retrospective study of autoimmune cerebellar ataxia over a 20-year period in a single institution
Authors: Akihiko Kudo
Hiroaki Yaguchi
Keiko Tanaka
Akio Kimura
Ichiro Yabe
Publication date: 23-08-2023
Publisher: Springer Berlin Heidelberg
Keyword: Paraneoplastic Cerebellar Degeneration
Published in: Journal of Neurology / Issue 1/2024
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-11946-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A retrospective study of autoimmune cerebellar ataxia over a 20-year period in a single institution

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Persistent cognitive slowing in post-COVID patients: longitudinal study over 6 months

MRI abnormalities in Creutzfeldt–Jakob disease and other rapidly progressive dementia

Pooled analysis of patients with inherited prion disease caused by two- to twelve-octapeptide repeat insertions in the prion protein gene (PRNP)

Correction to: Acute vestibular migraine: a ghost diagnosis in patients with acute vertigo

Hepatitis B reactivation is a rare event among patients with resolved infection undergoing anti-CD20 antibodies in monotherapy without antiviral prophylaxis: results from the HEBEM study

Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis